The DOI matches its Crossref record; 203 of the 203 references it cites were found in a registry or an index.
On Cell Loss and Selective Vulnerability of Neuronal Populations in Parkinson's Disease
Open accessAbstract
Significant advances have been made uncovering the factors that render neurons vulnerable in Parkinson's disease (PD). However, the critical pathogenic events leading to cell loss remain poorly understood, complicating the development of disease-modifying interventions. Given that the cardinal motor symptoms and pathology of PD involve the loss of dopamine (DA) neurons of the substantia nigra pars compacta (SNc), a majority of the work in the PD field has focused on this specific neuronal population. PD however, is not a disease of DA neurons exclusively: pathology, most notably in the form of Lewy bodies and neurites, has been reported in multiple regions of the central and peripheral nervous system, including for example the locus coeruleus, the dorsal raphe nucleus and the dorsal motor nucleus of the vagus. Cell and/or terminal loss of these additional nuclei is likely to contribute to some of the other symptoms of PD and, most notably to the non-motor features. However, exactly which regions show actual, well-documented, cell loss is presently unclear. In this review we will first examine the strength of the evidence describing the regions of cell loss in idiopathic PD, as well as the order in which this loss occurs. Secondly, we will discuss the neurochemical, morphological and physiological characteristics that render SNc DA neurons vulnerable, and will examine the evidence for these characteristics being shared across PD-affected neuronal populations. The insights raised by focusing on the underpinnings of the selective vulnerability of neurons in PD might be helpful to facilitate the development of new disease-modifying strategies and improve animal models of the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Braak staging is a method of classifying the progression of PD pathology and symptoms based on the presence of Lewy pathology (where 1 represents initial pathology in the brain stem, and 6, severe pathology including the neocortex) (21).”
MethodMDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,732
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., & Seitelberger, F. (1973) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(73)90175-5 · Cited by 2,651
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1437 · Cited by 1,756
Parkinson, J. (2002) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.14.2.223 · Cited by 1,628
Cited by
Parkinson’s disease: etiopathogenesis and treatment
Jankovic, J., & Tan, E. K. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322338 · Cited by 1,169
Selective neuronal vulnerability in Parkinson disease
Surmeier, D. J., Obeso, J. A., & Halliday, G. M. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.178 · Cited by 1,116
Ge, P., Dawson, V. L., & Dawson, T. M. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00367-7 · Cited by 496
Prodromal Parkinson disease subtypes — key to understanding heterogeneity
Berg, D., Borghammer, P., Fereshtehnejad, S.-M., Heinzel, S., Horsager, J., Schaeffer, E., & Postuma, R. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00486-9 · Cited by 409
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 365
Monzani, E., Nicolis, S., Dell'Acqua, S., Capucciati, A., Bacchella, C., Zucca, F. A., Mosharov, E. V., Sulzer, D., Zecca, L., & Casella, L. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201811122 · Cited by 271
Initiation and propagation of α-synuclein aggregation in the nervous system
Hijaz, B. A., & Volpicelli-Daley, L. A. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00368-6 · Cited by 262
Borghammer, P. (2021) · Journal of Parkinson's Disease · doi:10.3233/jpd-202481 · Cited by 259
Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?
Blesa, J., Foffani, G., Dehay, B., Bezard, E., & Obeso, J. A. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00542-9 · Cited by 232
Loss of SATB1 Induces p21-Dependent Cellular Senescence in Post-mitotic Dopaminergic Neurons
Riessland, M., Kolisnyk, B., Kim, T. W., Cheng, J., Ni, J., Pearson, J. A., Park, E. J., Dam, K., Acehan, D., Ramos-Espiritu, L. S., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.08.013 · Cited by 180
“In contrast, non-dopaminergic neuronal populations, such as cortical (CTX) neurons, are generally spared in the disease (Giguere et al., 2018; Kalia and Lang, 2015; Pedersen et al., 2005; Rajput and Rozdilsky, 1976).”
BackgroundAmelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin
Kam, T.-I., Park, H., Chou, S.-C., Van Vranken, J. G., Mittenbühler, M. J., Kim, H., A, M., Choi, Y. R., Biswas, D., Wang, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204835119 · Cited by 125
Molecular Mechanisms Underlying Synaptic and Axon Degeneration in Parkinson’s Disease
Gcwensa, N. Z., Russell, D. L., Cowell, R. M., & Volpicelli-Daley, L. A. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.626128 · Cited by 110
Fermented Soy Products: Beneficial Potential in Neurodegenerative Diseases
Jang, C. H., Oh, J., Lim, J. S., Kim, H. J., & Kim, J.-S. (2021) · Foods · doi:10.3390/foods10030636 · Cited by 100
La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98
“Moreover, the higher pacemaker activity and massive axonal arborization of Tg2576 DA neurons could contribute to their vulnerability, because of the high metabolic demand and need of increased mitochondrial efficiency (Giguère et al., 2018; Krashia et al., 2019b).”
BackgroundCalcium, Bioenergetics, and Parkinson’s Disease
Zampese, E., & Surmeier, D. J. (2020) · Cells · doi:10.3390/cells9092045 · Cited by 79
Apicco, D. J., Shlevkov, E., Nezich, C. L., Tran, D. T., Guilmette, E., Nicholatos, J. W., Bantle, C. M., Chen, Y., Glajch, K. E., Abraham, N. A., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006476118 · Cited by 64
Heng, N., Malek, N., Lawton, M. A., Nodehi, A., Pitz, V., Grosset, K. A., Ben‐Shlomo, Y., & Grosset, D. G. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13687 · Cited by 64
Extracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
Glia-derived extracellular vesicles in parkinson’s disease.
Marchetti, B., Leggio, L., L’Episcopo, F., Vivarelli, S., Tirolo, C., Paternò, G., Giachino, C., Caniglia, S., Serapide, M. F., & Iraci, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061941 · Cited by 38
Huntington, T. E., & Srinivasan, R. (2021) · Aging and disease · doi:10.14336/ad.2021.0517 · Cited by 34
Van Heesbeen, H. J., Von Oerthel, L., De Vries, P. M., Wagemans, C. M. R. J., & Smidt, M. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021387 · Cited by 12
Metadata
- Authors
- Giguère, N., Burke Nanni, S., & Trudeau, L.-E.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2018-06-19
- Volume
- 9
- Pages
- 455-455
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2806614570
- Cited by
- 413
- References
- 203
- FWCI
- 19.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.